Our hypotheses were that (1) the prescription rates of the new antidiabetic drugs such as DPP4, GLP1 analogues and SGLT2-inhibitors increased, (2) participants treated with the new drugs would achieve a better control of HbA1c or glucose levels than participants who do not receive them, and (3) participants with newly diagnosed T2D would benefit more frequently from the new antidiabetic drugs than participants with established T2D. The gene discussed is GCG; the disease is type 2 diabetes mellitus.